Antibody Information

General Information of This Antibody

Antibody ID	ANI0YVYHI
Antibody Name	AXL-733
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG1-kappa
Antigen Name	Tyrosine-protein kinase receptor UFO (AXL)	Antigen Info

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

AXL-733-MMAE [Investigative]

ADC Info

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 57.70% (Day 14)	Positive AXL expression (AXL+++/++)
Method Description	The anti-tumor activity of ADCs were determined in the pancreas cancer patient-derived xenograft (PDX) model PAXF1657. Before treatment,mice were divided into groups of 68 mice each,with equal tumor size distribution (average and variance). ADC is administered at a dose of 2.00 mg/kg in a single dose.
In Vivo Model	Pancreatic cancer PDX model (PDX: PAXF1657)
Experiment 2 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.30% (Day 14)	Positive AXL expression (AXL+++/++)
Method Description	The anti-tumor activity of ADCs were determined in the pancreas cancer patient-derived xenograft (PDX) model PAXF1657. Before treatment,mice were divided into groups of 68 mice each,with equal tumor size distribution (average and variance). ADC is administered at a dose of 4.00 mg/kg in a single dose.
In Vivo Model	Pancreatic cancer PDX model (PDX: PAXF1657)

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 28.20% (Day 18)	Positive AXL expression (AXL+++/++)
Method Description	In the LCLC-103H xenograft model,therapeutic treatment with a single dose of 1 mg/kg in anti-tumor activity in the AXL-ADC panel.
In Vivo Model	Lung cancer CDX model
In Vitro Model	Lung large cell carcinoma	LCLC-103H cells		CVCL_1375

References

Ref 1	Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nat Med. 2018 Feb;24(2):203-212.